Tharimmune: Funding, Investors & Team (Oct 2026)
Tharimmune, Inc. (Nasdaq: THAR) is a biotech company that is focused on developing a range of therapeutic options for rare immune, inflammatory, and oncological diseases. The company is currently working towards acquiring a clinical-stage asset that has shown promise in alleviating chronic, debilitating itching in a rare liver disease called primary biliary cholangitis (PBC), which currently has no known cure. Furthermore, Tharimmune is also conducting research in the field of immuno-oncology, with a pipeline of early-stage treatments that utilize unique antibodies to target specific areas in various solid tumors. Their collaboration with OmniAb, Inc. allows them access to an antibody discovery technology platform for specified targets. For additional information, please visit their website at www.tharimmune.com.
Tharimmune has raised $14.1M across 3 funding rounds on record, the most recent an undisclosed round of $2.0M announced in Dec 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Tharimmune Company Profile and Key Stats
Latest funding round on record: Dec 2024.
Tharimmune Funding Rounds
Tharimmune raised $10.0M in an undisclosed round announced in Nov 2023.
7 months later, an undisclosed round of $2.1M was announced in Jun 2024.
6 months later, an undisclosed round of $2.0M was announced in Dec 2024.
Tharimmune Founders and Leadership Team
Contact details for the Tharimmune team: 1 of 1 has an email address on file.
Start 14-day free trial →Tharimmune Funding Compared to Other Biotechnology Startups
Tharimmune's latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Tharimmune in Biotechnology and Chester
Companies Similar to Tharimmune
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Tharimmune Funding FAQs
What does Tharimmune do?
Tharimmune, Inc. (Nasdaq: THAR) is a biotech company that is focused on developing a range of therapeutic options for rare immune, inflammatory, and oncological diseases. The company is currently working towards acquiring a clinical-stage asset that has shown promise in alleviating chronic, debilitating itching in a rare liver disease called primary biliary cholangitis (PBC), which currently has no known cure. Furthermore, Tharimmune is also conducting research in the field of immuno-oncology, with a pipeline of early-stage treatments that utilize unique antibodies to target specific areas in various solid tumors. Their collaboration with OmniAb, Inc. allows them access to an antibody discovery technology platform for specified targets. For additional information, please visit their website at www.tharimmune.com.
How much funding has Tharimmune raised?
Tharimmune has raised $14.1M across 3 rounds on record. The most recent is an undisclosed round of $2.0M announced in Dec 2024.
When did Tharimmune last raise funding?
Tharimmune's most recent funding round on record is an undisclosed round of $2.0M, announced in Dec 2024.
Who founded Tharimmune?
FundedIQ lists Randy Milby (Founder) at Tharimmune.
Where is Tharimmune headquartered?
Tharimmune is based in Chester, Cheshire, United Kingdom.
How many employees does Tharimmune have?
Tharimmune is in the 1-10 employee band.
How does Tharimmune's funding compare to other Biotechnology startups?
Tharimmune's latest round of $2.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Tharimmune Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tharimmune is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.